

## MIRA INFORM REPORT

|                      |            |
|----------------------|------------|
| <b>Report No. :</b>  | 528903     |
| <b>Report Date :</b> | 08.09.2018 |

### IDENTIFICATION DETAILS

|                                     |   |
|-------------------------------------|---|
| <b>Name :</b>                       | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD.  |
| <b>Registered Office :</b>          | No. 1 North Outer Ring Road, Feixian County, Shandong Province 273400 PR  |
| <b>Country :</b>                    | China   |
| <b>Financials (as on) :</b>         | 31.12.2016  |
| <b>Date of Incorporation :</b>      | 30.03.2001  |
| <b>Unified Social Credit Code :</b> | 9137130072755352X1  |
| <b>Legal Form :</b>                 | Chinese Foreign Equity Joint Venture Enterprise   |
| <b>Line of Business :</b>           | Subject registered business scope includes manufacturing and selling Chinese patent medicines, chemical medicines, bioengineering products, biological products, pharmaceutical intermediates, APIs, aseptic bulk drugs, psychotropic substances, chemical raw materials, chemical products, packaging materials; accommodation, catering, food management. |
| <b>No. of Employees :</b>           | 3,880   |

### RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23<sup>rd</sup> January 2017)

|                        |    |
|------------------------|----|
| <b>MIRA's Rating :</b> | A+ |
|------------------------|----|

| Credit Rating | Explanation | Rating Comments  |
|---------------|-------------|--|
| A+            | Low Risk    | Business dealings permissible with low risk of default |

|                 |           |
|-----------------|-----------|
| <b>Status :</b> | Excellent |
|-----------------|-----------|

**DISCLAIMER :** This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

|                            |         |
|----------------------------|---------|
| <b>Payment Behaviour :</b> | Regular |
| <b>Litigation :</b>        | Clear   |

**NOTES :**

Any query related to this report can be made on e-mail : [infodept@mirainform.com](mailto:infodept@mirainform.com) while quoting report number, name and date.

**ECGC Country Risk Classification List**

| <b>Country Name</b> | <b>Previous Rating<br/>(31.12.2017)</b> | <b>Current Rating<br/>(01.04.2018)</b> |
|---------------------|---|--|
| China               | A2                                      | A1                                     |

| <b>Risk Category</b> | <b>ECGC Classification</b> |
|----------------------|----------------------------|
| Insignificant        | A1                         |
| Low Risk             | A2                         |
| Moderately Low Risk  | B1                         |
| Moderate Risk        | B2                         |
| Moderately High Risk | C1                         |
| High Risk            | C2                         |
| Very High Risk       | D                          |

**CHINA - ECONOMIC OVERVIEW**

Since the late 1970s, China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role. China has implemented reforms in a gradualist fashion, resulting in efficiency gains that have contributed to a more than tenfold increase in GDP since 1978. Reforms began with the phaseout of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China continues to pursue an industrial policy, state support of key sectors, and a restrictive investment regime. From 2013 to 2017, China had one of the fastest growing economies in the world, averaging slightly more than 7% real growth per year. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2017 stood as the largest economy in the world, surpassing the US in 2014 for the first time in modern history. China became the world's largest exporter in 2010, and the largest trading nation in 2013. Still, China's per capita income is below the world average.

In July 2005 moved to an exchange rate system that references a basket of currencies. From mid-2005 to late 2008, the renminbi (RMB) appreciated more than 20% against the US dollar, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing announced it would resume a gradual appreciation. From 2013 until early 2015, the renminbi held steady against the dollar, but it depreciated 13% from mid-2015 until end-2016 amid strong capital outflows; in 2017 the RMB resumed appreciating against the dollar – roughly 7% from end-of-2016 to end-of-2017. In 2015, the People's Bank of China announced it would continue to carefully push for full convertibility of the renminbi, after the currency was accepted as part of the IMF's special drawing rights basket. However, since late 2015 the Chinese Government has strengthened capital controls and oversight of overseas investments to better manage the exchange rate and maintain financial stability.

The Chinese Government faces numerous economic challenges including: (a) reducing its high domestic savings rate and correspondingly low domestic household consumption; (b) managing its high corporate debt burden to maintain financial stability; (c) controlling off-balance sheet local government debt used to finance infrastructure stimulus; (d) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and college graduates, while maintaining competitiveness; (e) dampening speculative investment in the real estate sector without sharply slowing the economy; (f) reducing industrial overcapacity; and (g) raising productivity growth rates through the more efficient allocation of capital and state-support for innovation. Economic development has progressed further in coastal provinces than in the interior, and by 2016 more than 169.3 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of China's population control policy known as the "one-child policy" - which was relaxed in 2016 to permit all families to have two children - is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and urbanization. The Chinese Government is seeking to add energy production capacity from sources other than coal and oil, focusing on natural gas, nuclear, and clean energy development. In 2016, China ratified the Paris Agreement, a multilateral agreement to combat climate change, and committed to peak its carbon dioxide emissions between 2025 and 2030.

The government's 13th Five-Year Plan, unveiled in March 2016, emphasizes the need to increase innovation and boost domestic consumption to make the economy less dependent on government investment, exports, and heavy industry. However, China has made more progress on subsidizing innovation than rebalancing the economy. Beijing has committed to giving the market a more decisive role in allocating resources, but the Chinese Government's policies continue to favor state-owned enterprises and emphasize stability. Chinese

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.



**MIRA INFORM PRIVATE LIMITED**  
605, Palmspring, Near D'Mart, Link Road,  
Malad (West), Mumbai - 400 064. INDIA  
Tel : 91-22-40448000 (44 lines)  
Fax : 91-22-40448045 / 40448046  
E-mail : mira@mirainform.com  
info@mirainform.com  
Website : <http://www.mirainform.com>  
<http://www.miraglobalcheck.com>  
<http://www.miraglobalcollections.com>

leaders in 2010 pledged to double China's GDP by 2020, and the 13th Five Year Plan includes annual economic growth targets of at least 6.5% through 2020 to achieve that goal. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. Chinese leaders also have undermined some market-oriented reforms by reaffirming the "dominant" role of the state in the economy, a stance that threatens to discourage private initiative and make the economy less efficient over time. The slight acceleration in economic growth in 2017—the first such uptick since 2010—gives Beijing more latitude to pursue its economic reforms, focusing on financial sector deleveraging and its Supply-Side Structural Reform agenda, first announced in late 2015.

Source : CIA

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

## **COMPANY NAME AND ADDRESS**

|  |   |
|--|---|
| <b>COMPANY NAME</b>                            | Shandong New Time Pharmaceutical Co., Ltd.  |
| <b>CURRENT ADDRESS/<br/>REGISTERED ADDRESS</b> | No. 1 North Outer Ring Road, Feixian County, Shandong Province 273400<br>PR China |
| <b>TEL. NO.</b>                                | 86 (0) 539-5030558/5030628/5030788  |
| <b>FAX NO.</b>                                 | 86 (0) 539-5030600  |

## **EXECUTIVE SUMMARY**

|                            |   |
|----------------------------|---|
| DATE OF REGISTRATION       | : MARCH 30, 2001                                  |
| UNIFIED SOCIAL CREDIT CODE | : 9137130072755352X1                              |
| LEGAL FORM                 | : CHINESE FOREIGN EQUITY JOINT VENTURE ENTERPRISE |
| CHIEF EXECUTIVE            | : ZHANG GUIMIN (LEGAL REPRESENTATIVE)             |
| REGISTERED CAPITAL         | : CNY 363,908,000                                 |
| STAFF                      | : 3,880   |
| BUSINESS CATEGORY          | : MANUFACTURING & TRADING                         |
| REVENUE                    | : CNY 2,823,670,000 (AS OF DEC. 31, 2016)         |
| EQUITIES                   | : CNY 5,482,160,000 (AS OF DEC. 31, 2016)         |
| WEBSITE                    | : N/A   |
| E-MAIL                     | : N/A   |
| PAYMENT                    | : REGULAR   |
| MARKET CONDITION           | : COMPETITIVE                                     |
| FINANCIAL CONDITION        | : FAIRLY GOOD                                     |
| OPERATIONAL TREND          | : FAIRLY STEADY                                   |
| GENERAL REPUTATION         | : FAIRLY GOOD                                     |

Adopted abbreviations (as follows)

**SC** - Subject Company (the company inquired by you)

**N/A** – Not available

**CNY** – China Yuan Ren Min Bi

## **OPERATIONAL TREND & GENERAL REPUTATION**

This section aims at indicating the relative positions of SC in respect of its operational trend & general reputation

Operational Trend:-

Upward

Steady

Fairly Steady

General Reputation:-

Excellent

Good

Fairly Good

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

|                       |                       |
|-----------------------|-----------------------|
| Ordinary              | Average               |
| Fair                  | Fair                  |
| Stagnant              | Detrimental           |
| Downward              | Not known             |
| Not known             | Not yet be determined |
| Not yet be determined |                       |

## **LEGAL STATUS & HISTORY**

SC was established as Chinese foreign equity joint venture enterprise of PRC with State Administration of Industry & Commerce (SAIC) under unified social credit code: 9137130072755352X1.

SC's registered capital: CNY 363,908,000

SC's paid-in capital: CNY 363,908,000

### **Registration Change Record:-**

| <b>Date</b> | <b>Change of Contents</b>                   | <b>Before the change</b>   | <b>After the change</b>                    |
|-------------|---|--|--|
| 2001-09-18  | Company Name                                | Linyi Lunan Pharmaceutical Group Yimeng Pharmaceutical Co., Ltd. | Linyi New Time Pharmaceutical Co., Ltd.    |
| 2002-06-11  | Legal Representative                        | Shen Xiaoguo   | Zhao Zhiquan                               |
|             | Registered Capital                          | CNY 3,200,000  | CNY 30,000,000                             |
| 2003-12-24  | Company Name                                | Linyi New Time Pharmaceutical Co., Ltd.                          | Shandong New Time Pharmaceutical Co., Ltd. |
| 2005-02-05  | Registered Capital                          | CNY 30,000,000   | CNY 63,600,000                             |
| 2005-06-01  | Registered Capital                          | CNY 63,600,000   | CNY 105,000,000                            |
| 2007-03-23  | Registered capital                          | CNY 105,000,000  | CNY 189,000,000                            |
| 2014-12-18  | Legal Representative                        | Zhao Zhiquan   | Zhang Guimin                               |
| 2015-11-23  | Registration No./Unified Social Credit Code | 371300400000357  | 9137130072755352X1                         |
| 2016-12-14  | Registered Capital                          | CNY 189,000,000  | CNY 363,908,000                            |

### **Current Co search indicates SC's shareholders & chief executives are as follows:-**

| <b>Name of Shareholder (s)</b>            | <b>% of Shareholding</b> |
|---|--------------------------|
| Anderson Investment Co., Ltd. (B.V.I.)    | 25                       |
| Lunan Pharmaceutical Group Corporation    | 70.85                    |
| Long Guangxia                             | 2.6                      |
| Beijing Tianheng Pharmaceutical Institute | 1.55                     |

### **SC's Chief Executives:-**

| <b>Position</b> | <b>Name</b> |
|-----------------|-------------|
|-----------------|-------------|

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Legal Representative and Chairman  
General Manager and Director  
Director

Zhang Guimin  
Li Guanzhong  
Wang Buqiang  
Zhang Lixing  
Liu Zhong  
Liu Changcheng  
Xu Bingnan

Supervisor

## **RECENT DEVELOPMENT**

No recent development was found during our checks at present.

## **SHAREHOLDER CHART & BACKGROUND**

| <b>Name</b>                               | <b>% of Shareholding</b> |
|---|--------------------------|
| Lunan Pharmaceutical Group Corporation    | 70.85                    |
| Anderson Investment Co., Ltd. (B.V.I.)    | 25                       |
| Long Guangxia                             | 2.6                      |
| Beijing Tianheng Pharmaceutical Institute | 1.55                     |

Lunan Pharmaceutical Group Corporation  
-----

Date of Registration: December 14, 1995  
Unified Social Credit Code: 913700006139918126  
Chief Executive: Zhao Guimin  
Registered Capital: CNY 81,705,000  
Tel: 86 (0) 539-8331258  
Fax: 86 (0) 539-8331269  
Website: [www.lunan.com.cn](http://www.lunan.com.cn)  
E-mail: [ibo@lunan.com.cn](mailto:ibo@lunan.com.cn)

Beijing Tianheng Pharmaceutical Institute  
-----

Unified Social Credit Code: 91110102634376691B  
Date of Registration: July 27, 1998  
Registered Capital: CNY 6,000,000  
Chief Executive: Jiang Qingwei

## **MANAGEMENT**

### **Zhang Guimin, Legal Representative and Chairman**

-----  
Gender: M  
Nationality: China  
Qualification: University  
Working experience (s):

From 2014 to present, working in SC as legal representative and chairman, also working in Lunan Pharmaceutical Group Corporation, Lunan New Time Biotechnology Co., Ltd., Chongqing Fujin Bio-Medicine Co., Ltd., Lunan New Time Pharmaceutical Co., Ltd., Lunan Hope Pharmaceutical Co., Ltd. and Lunan Better Pharmaceutical Co., Ltd. as legal representative

### **Li Guanzhong, General Manager and Director**

-----  
Gender: M  
Nationality: China  
Qualification: University  
Working experience (s):

At present, working in SC as deputy general manager and director

### **Director**

-----  
Wang Buqiang  
Zhang Lixing  
Liu Zhong  
Liu Changcheng

### **Supervisor**

-----  
Xu Bingnan

## **BUSINESS OPERATION**

SC's registered business scope includes manufacturing and selling Chinese patent medicines, chemical medicines, bioengineering products, biological products, pharmaceutical intermediates, APIs, aseptic bulk drugs, psychotropic substances, chemical raw materials, chemical products, packaging materials; accommodation, catering, food management.

SC is mainly engaged in manufacturing and selling pharmaceutical products.

SC's products mainly include: Faropenem Sodium, Ketorolac Tromethamine, 4-AA, Tamsulosin HCl, Sevoflurane, Isoflurane, clavulanate potassium, 7-adca, Isosorbide Mononitrate, Isosorbide Dinitrate, Milrinone, Moclobemide,

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Mosapride Citrate, Sotalol Hydrochloride, Acipimox, Alfuzosin Hydrochloride, Aniracetam, Cetirizine Hydrochloride, Chlorzoxazone, Epirubicin Hydrochloride.

SC sources its materials 100% from domestic market. SC sells 70% of its products in domestic market, and 30% to the overseas market, mainly India, Korea, Pakistan, Iran, Egypt, Brazil, Spain, Syria, Turkey, and Philippines.

The buying terms of SC include Check, T/T and Credit of 30-60 days. The payment terms of SC include T/T, L/C and Credit of 30-60 days.

\*Major Customer:

=====  
Lunan Hope Pharmaceutical Co., Ltd.  
Lunan Better Pharmaceutical Co., Ltd.  
Laboratorios Pisa, S.A.  
Parenteral Drugs India Ltd.  
Keystone Healthcare

**Staff & Office:**

-----  
SC is known to have approx. 3,880 staff at present.

SC owns an area as its operating office & factory of approx. 1,182,250 sq. meters at the heading address.

## ***RELATED COMPANY***

**SC is known to have the following subsidiaries at present,**

Lunan New Time Biotechnology Co., Ltd.

Chongqing Fujin Bio-Medicine Co., Ltd.

Lunan New Time Pharmaceutical Co., Ltd.

Lunan Hope Pharmaceutical Co., Ltd.

Lunan Better Pharmaceutical Co., Ltd.

## ***PAYMENT***

**Overall payment appraisal:**

( ) Excellent ( ) Good (X) Average ( ) Fair ( ) Poor ( ) Not yet be determined

The appraisal serves as a reference to reveal SC's payments habits and ability to pay. It is based on the 3 weighed factors: Trade payment experience (through current enquiry with SC's suppliers), our delinquent payment records and our debt collection record concerning SC.

**DISCLAIMER :** This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

**Trade payment experience:** SC did not provide any name of trade/service suppliers and we have no other sources to conduct the enquiry at present.

**Delinquent payment record:** None in our database.

**Debt collection record:** No overdue amount owed by SC was placed to us for collection within the last 6 years.

## **BANKING**

### **Basic Bank:**

Industrial & Commercial Bank of China Feixian Sub-branch

AC#: 1610020809022107543

## **FINANCIALS**

### **Financial Summary**

| Unit: CNY'000     | <b>As of Dec.<br/>31, 2013</b> | <b>As of Dec.<br/>31, 2014</b> | <b>As of Dec.<br/>31, 2015</b> | <b>As of Dec.<br/>31, 2016</b> |
|-------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Total assets      | 4,125,520                      | 4,343,370                      | 4,657,967                      | 8,061,590                      |
| Total liabilities | 2,534,550                      | 2,596,140                      | 2,677,540                      | 2,579,430                      |
| Equities          | 1,590,970                      | 1,747,230                      | 1,980,427                      | 5,482,160                      |
| Revenue           | 1,819,980                      | 2,034,520                      | 2,311,309                      | 2,823,670                      |
| Profit before tax | 281,950                        | 174,820                        | 262,411                        | --                             |
| Less: profit tax  | 1,210                          | 16,010                         | 28,941                         | --                             |
| Profits           | 280,740                        | 158,810                        | 233,470                        | 314,490                        |

### **Important Ratios**

|                             | <b>As of Dec.<br/>31, 2013</b> | <b>As of Dec.<br/>31, 2014</b> | <b>As of Dec.<br/>31, 2015</b> | <b>As of Dec.<br/>31, 2016</b> |
|-----------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| *Liabilities to assets      | 0.61                           | 0.60                           | 0.57                           | 0.32                           |
| *Net profit margin (%)      | 15.42                          | 7.81                           | 10.10                          | 11.14                          |
| *Return on total assets (%) | 6.80                           | 3.66                           | 5.01                           | 3.90                           |
| *Revenue/Total assets       | 0.44                           | 0.47                           | 0.50                           | 0.35                           |

**DISCLAIMER :** This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

## **FINANCIAL COMMENTS**

### **PROFITABILITY: FAIRLY GOOD**

The revenue of SC appears fairly good in its line.  
SC's net profit margin is fairly good.  
SC's return on total assets is average.

### **LIQUIDITY: FAIR**

SC's revenue is in a fair level, comparing with the size of its total assets.

### **LEVERAGE: FAIRLY GOOD**

The debt ratio of SC is average.  
The risk for SC to go bankrupt is low.

**Overall financial condition of the SC: Fairly Good.**

## **CONCLUSIONS**

SC is considered large-sized in its line with fairly good financial conditions.

**FOREIGN EXCHANGE RATES**

| Currency  | Unit | Indian Rupees |
|-----------|------|---------------|
| US Dollar | 1    | INR 71.90     |
| UK Pound  | 1    | INR 93.04     |
| Euro      | 1    | INR 83.67     |
| CNY       | 1    | INR 10.54     |

**Note :** Above are approximate rates obtained from sources believed to be correct

**INFORMATION DETAILS**

|                      |     |
|----------------------|-----|
| Analysis Done by :   | VIV |
| Report Prepared by : | TRU |

**DISCLAIMER :** This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

**RATING EXPLANATIONS**

| Credit Rating | Explanation      | Rating Comments  |
|---------------|------------------|--|
| A++           | Minimum Risk     | Business dealings permissible with minimum risk of default     |
| A+            | Low Risk         | Business dealings permissible with low risk of default         |
| A             | Acceptable Risk  | Business dealings permissible with moderate risk of default    |
| B             | Medium Risk      | Business dealings permissible on a regular monitoring basis    |
| C             | Medium High Risk | Business dealings permissible preferably on secured basis      |
| D             | High Risk        | Business dealing not recommended or on secured terms only      |
| NB            | New Business     | No recommendation can be done due to business in infancy stage |
| NT            | No Trace         | No recommendation can be done as the business is not traceable |

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)